Bluffton, SC, United States of America

Riccardo Panicucci

USPTO Granted Patents = 1 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Riccardo Panicucci: Innovator in Cholangiocarcinoma Treatment

Introduction

Riccardo Panicucci is a notable inventor based in Bluffton, SC (US). He has made significant contributions to the field of medicine, particularly in the treatment of cholangiocarcinoma, a rare and aggressive form of cancer. His innovative approach has the potential to improve patient outcomes and advance cancer treatment methodologies.

Latest Patents

Riccardo Panicucci holds a patent for "Methods of treating cholangiocarcinoma." This patent outlines methods for treating advanced or metastatic cholangiocarcinoma in patients by administering infigratinib or a pharmaceutically acceptable salt thereof. This treatment is particularly relevant for patients who have experienced progression of the disease after previous therapies. He has 1 patent to his name, showcasing his commitment to advancing medical science.

Career Highlights

Panicucci is associated with QED Therapeutics, Inc., where he applies his expertise to develop innovative treatments. His work focuses on addressing unmet medical needs in oncology, particularly for patients suffering from challenging conditions like cholangiocarcinoma. His dedication to research and development has positioned him as a key figure in the fight against cancer.

Collaborations

Throughout his career, Riccardo has collaborated with esteemed colleagues, including Michael Monteith and Gang Li. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas, ultimately benefiting the field of cancer treatment.

Conclusion

Riccardo Panicucci's contributions to the treatment of cholangiocarcinoma exemplify the impact of innovative thinking in medicine. His patent and work at QED Therapeutics, Inc. highlight his commitment to improving patient care and advancing cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…